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A B S T R A C T
The peri-infarct region after ischemic stroke is the anatomical location for many of the endogenous recovery
processes; however, -the molecular events in the peri-infarct region remain poorly characterized. In this study,
we examine the molecular profile of the peri-infarct region on post-stroke day four, a time when reparative
processes are ongoing. We used a multiomics approach, involving RNA sequencing, and mass spectrometry-
based proteomics and metabolomics to characterize molecular changes in the peri-infarct region. We also took
advantage of our previously developed method to express transgenes in the peri-infarct region where self-
complementary adeno-associated virus (AAV) vectors were injected into the brain parenchyma on post-stroke
day 2. We have previously used this method to show that mesencephalic astrocyte-derived neurotrophic factor
(MANF) enhances functional recovery from stroke and recruits phagocytic cells to the peri-infarct region. Here,
we first analyzed the effects of stroke to the peri-infarct region on post-stroke day 4 in comparison to sham-
operated animals, finding that strokeinduced changes in 3345 transcripts, 341 proteins, and 88 metabolites. We
found that after stroke, genes related to inflammation, proliferation, apoptosis, and regeneration were upre-
gulated, whereas genes encoding neuroactive ligand receptors and calcium-binding proteins were down-
regulated. In proteomics, we detected upregulation of proteins related to protein synthesis and downregulation
of neuronal proteins. Metabolomic studies indicated that in after stroke tissue there is an increase in saccharides,
sugar phosphates, ceramides and free fatty acids and a decrease of adenine, hypoxantine, adenosine and gua-
nosine. We then compared the effects of post-stroke delivery of AAV1-MANF to AAV1-eGFP (enhanced green
fluorescent protein). MANF administration increased the expression of 77 genes, most of which were related to
immune response. In proteomics, MANF administration reduced S100A8 and S100A9 protein levels. In meta-
bolomics, no significant differences between MANF and eGFP treatment were detected, but relative to sham
surgery group, most of the changes in lipids were significant in the AAV-eGFP group only. This work describes
the molecular profile of the peri-infarct region during recovery from ischemic stroke, and establishes a resource
for further stroke studies. These results provide further support for parenchymal MANF as a modulator of
phagocytic function.
1. Introduction
Stroke is the second most common cause of death and a significant
cause of disability worldwide (Feigin et al., 2014). There are no phar-
macological treatments for stroke besides thrombolysis with tissue
plasminogen activators, which should be administered within hours
from the ischemic stroke onset (Powers et al., 2018). While the majority
of the patients survive, most require rehabilitation and complete
functional recovery is unusual (Benjamin et al., 2019). Therefore, un-
derstanding the neurobiology of recovery and brain repair is important
in order to develop drugs hastening the recovery from stroke. On the
molecular level, multiple early mechanisms have been shown to play a
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role in stroke-induced cell and tissue damage, including glutamatergic
excitotoxicity, calcium dysregulation, oxidative stress, cortical
spreading depolarizations, inflammation, and finally, cell death
(Moskowitz et al., 2010). The apoptotic cell death ceases by the second
day post-stroke, while by day 4, the endogenous recovery mechanisms
are thought to be activated (Li et al., 2000; Liu et al., 2009; Mulcahy
et al., 2003).
Upon ischemic stroke, the core of the ischemic lesion suffers from
complete loss of blood flow, inducing necrosis within minutes. In con-
trast, in the peri-infarct region surrounding the core area, the tissue
damage is less pronounced. The cellular events in the peri-infarct region
are characterized by recruitment of neutrophils, which are subse-
quently replaced by increasing numbers of macrophages/microglia
(Anttila et al., 2018; Gesuete et al., 2016; Rayasam et al., 2018). At the
same time, reactive astrocytes start to accumulate in the peri-infarct
area, leading to the formation of an astrocytic scar around the lesion
core (Anttila et al., 2018). At the anatomical level, functional recovery
from stroke can be due to neuronal rearrangement (plasticity) in the
peri-infarct region or due to remodeling of neuronal connectivity in the
contralateral hemisphere (Brown et al., 2009; Brown et al., 2007; Li and
Murphy, 2008). Another brain repair mechanism can involve the mi-
gration of neural progenitors and their partial integration to the peri-
infarct region (Liang et al., 2019). Nevertheless, the post-stroke peri-
infarct region remains poorly characterized.
We have previously developed a method for targeting adeno-asso-
ciated virus (AAV) vectors to the peri-infarct region and investigating
the effect of local transgene expression on the post-stroke events in rats
(Mätlik et al., 2014). By using this technique we found that ectopic
expression of MANF in the peri-infarct area hastens the behavioral re-
covery after stroke as well as increases the number of phagocytic cells
in the peri-infarct region (Mätlik et al., 2018). In addition, we have
found MANF to be important for cortical development, neuronal ex-
tensions in differentiating cells, and modulating STAT3 phosphoryla-
tion in neurosphere cultures (Tseng et al., 2018; Tseng et al., 2017).
However, the detailed mechanism of how MANF protects and restores
the neurons in stroke is unclear. It seems likely that endogenous en-
doplasmic reticulum (ER) luminal MANF mediates proper protein
folding (Yan et al., 2019), but the mechanism of MANF's action in the
extracellular space remains unknown. While the plasma membrane
receptor for extracellularly applied MANF remains elusive (Hellman
et al., 2011), plasma membrane sulfatides have been indicated to bind
MANF, inducing its cellular uptake (Bai et al., 2018).
The aim of this work was to study the molecular events occurring in
the peri-infarct region during the initial phase of the recovery from
ischemic stroke and to elucidate the effects of AAV-MANF treatment on
these events. While individual omics technologies have been success-
fully applied to the study of brain tissue in stroke (Brea et al., 2015; Irie
et al., 2014; Li et al., 2015), each technique has its limitations. Pro-
ducing systems level information with multiple omics technologies
poses a way to overcome these limitations. Using the distal middle
cerebral artery occlusion (dMCAo) model of ischemic stroke in rats,
followed by global, untargeted analysis of the transcriptome, proteome,
and metabolome, we identified widespread changes induced by stroke,
as expected, and immune response modulation by MANF. This is, to our
knowledge, the first multiomics description of the molecular phe-
nomena occurring in the ischemic peri-infarct area during the recovery
from ischemic stroke, thus serving as a resource for future studies.
2. Materials and methods
2.1. Sample processing
The experimental design is presented in Fig. 1.
2.1.1. Animals
Male Sprague Dawley rats (age 7–8 weeks, weight 200–280 g,
Envigo, Netherlands) were used. All animal experiments were con-
ducted according to the 3R principles of EU directive 2010/63/EU on
the care and use of experimental animals, local laws and regulations,
and were approved by the national Animal Experiment Board of
Finland (protocol approval number ESAVI/7812/04.10.07/2015). The
animals were housed in groups of 4 with ad libitum access to food and
water under a 12 h/12 h dark-light cycle and the well-being of the
animals was monitored daily.
2.1.2. dMCAo and AAV injections
The right middle cerebral artery (MCA) and bilateral common car-
otid arteries (CCAs) were ligated as previously described (Airavaara
et al., 2010; Airavaara et al., 2009; Mätlik et al., 2018; Mätlik et al.,
2014). Briefly, rats were anesthetized with 4% chloral hydrate in-
traperitoneally (10 mL/kg, Sigma). CCAs were identified and isolated
through a ventral midline cervical incision. A craniotomy was made on
the right hemisphere and the distal branch of the right MCA was ligated
with a 10–0 suture, followed by occlusion of CCAs with non-traumatic
arterial clips. After 60 min, the suture around the MCA and arterial clips
were removed. Body temperature of the animals was maintained at
37 °C. After recovery from anesthesia, the rats were returned to their
home cage. The sham operated animals went through all the same
procedures except the arteries were not ligated.
One day later, the neurological deficits of the stroke animals were
evaluated with body asymmetry test and Bederson's score as previously
described (Mätlik et al., 2018) and the rats were divided into equal
groups to receive either AAV-MANF (human) or AAV-eGFP intracranial
injections. On day 2 after dMCAo surgery, the animals were anesthe-
tized with isoflurane and stereotaxic injections were performed as
previously described (Mätlik et al., 2014). Briefly, 2.5 μL of AAV1-eGFP
or AAV1-MANF was injected at a speed of 1 μL/min using a 10 μL
Hamilton syringe with a 30-gauge blunt needle into two subcortical
sites (A/P + 1.6, L/M+ 2.2, D/V− 5.0 and A/P− 0.4, L/M+ 4.0, D/
V − 5.0). The needle was kept in place for 2 min after the injection to
prevent backflow.
2.1.3. Sample collection
Two days after the AAV injections, rats were anesthetized by pen-
tobarbital and perfused for 5 min with body temperature saline, brains
were rapidly frozen in −50 °C isopentane and stored at −80 °C. The
peri-infarct area was cryo-dissected with a punch as previously de-
scribed (Airavaara et al., 2011). Unilateral tissue punches for the pro-
teomic and metabolomics analysis from the peri-infarct region (ap-
proximate AP levels of +2 and + 0 mm) were taken from 1 mm
coronal sections cut in a cryostat at −20 °C (Fig. 1). For the tran-
scriptomic analysis, the samples were taken from the AP level + 1 from
1 mm coronal sections. The samples were kept frozen at −80 °C until
subsequent transcriptomic, proteomic, and metabolomics processing.
Proteomic and metabolomics analyses were performed on the same set
of samples (N = 10, 9, and 11 for SHAM, AAV-eGFP, and AAV-MANF
groups, respectively), whereas a separate set of samples was used for
transcriptomics (N = 8 for all three sample groups).
2.1.4. Homogenization of samples for proteomics and metabolomics
The brain punch samples were thawed and weighed into tubes
containing approximately 100 mg zirconia beads (1.0 mm diameter,
BioSpec Products, Bartlesville, OK, USA). Tissue masses varied from 1.7
to 10.4 mg per sample. 30 μL of Milli-Q water per 1 mg of tissue was
added, and the samples were homogenized with FastPrep-24 5G
homogenizer (MP Biomedicals, LLC, Santa Ana, CA, USA) using one 40-
s cycle with speed 6.0 m/s. The homogenates were centrifuged for
5 min at 8000 G at 4 °C to break the foam and stored at −80 °C.
Samples were thawed and divided into three aliquots: one aliquot was
used for positive ion mode metabolomics, one for negative ion mode
metabolomics, and one for proteomics. Due to insufficient sample
mass/volume, one AAV-MANF sample (C_11) and one SHAM sample
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(A_03) were not analyzed with the negative ion mode metabolomics
method. One blank sample (6 μL of Milli-Q water) was processed like
the brain samples and used in the metabolomics analysis (SP_blank,
Data S3).
During homogenization, red hue indicating residual blood was ob-
served in 12 samples by visual inspection (Fig. S1A). To account for the
artifacts caused by the molecules from blood, the correlation of each
protein and metabolite abundance with serum albumin is shown in the
results using the color gradient presented in Fig. S1B, but no filtering of
the results based on these correlations was applied (described in detail
in the supplementary material).
2.2. Transcriptomics
2.2.1. Sample handling
RNA was extracted with Trizol reagent and treated with DNase
(Ambion; #1906). Total RNA concentration and quality were de-
termined with NanoDrop 1000 v3.7.1 and Agilent 2100 Bioanalyzer.
Genomic DNA was removed from samples using Heat&Run gDNA re-
moval kit, and cleanup and size selection (removal of small fragments)
was done using Agencourt AMPure XP. rRNA was removed and the
sequencing libraries were prepared using Illumina TruSeq Stranded
Total RNA Library Prep Kit with Ribo-Zero Human/Mouse/Rat and
sequenced on Illumina NextSeq 500 instrument using 75 bp kit.
2.2.2. Data processing
Adapter sequences and low quality reads were removed from the
data using trimmomatic 0.36 (Bolger et al., 2014). Leftover rRNA reads
were removed using SortMeRNA 2.1 (Kopylova et al., 2012). The data
was mapped to Rattus norvegicus genome Rnor_6.0 using STAR 2.6.1d
(Dobin et al., 2013). The original genome sequence and annotation was
augmented with sequence and annotation for human MANF and eGFP.
Count data was processed using GenomicFeatures 1.34.3 and Genomi-
cAlignments 1.18.1 (Lawrence et al., 2013), and the differential ex-
pression analysis carried out using DESeq2 1.22.2 (Love et al., 2014).
Changes with q-value<0.01 and fold change> 2 were considered
significant. Gene Ontology (GO) (The Gene Ontology Consortium,
2019; 2017) and Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Kanehisa and Goto, 2000) pathway enrichment analysis was per-
formed with DAVID 6.8 (Huang et al., 2009a, 2009b), using the col-
lapsed (DIR) GO terms.
The data have been deposited in the ArrayExpress database at
EMBL-EBI (www.ebi.ac.uk/arrayexpress) under the accession number
E-MTAB-8339.
2.2.3. Gene set enrichment analysis (GSEA)
For GSEA, we used minimally overlapping manually curated gene
sets (suppl data table ‘gene sets’) based on transcriptomes of microglia,
oligodendroglia, astrocytes, neurons, endothelial cells, and oligoden-
drocyte precursors from mouse cerebral cortex (Zhang et al., 2014) and
mouse immune cell transcriptomes of macrophages from peritoneal
cavity and granulocytes, dendritic cells, natural killer cells, B-2 B cells
and T cells (not differentiating between CD4+, CD8+, T-reg and
gamma delta T subtypes) from spleen (Gal-Oz et al., 2019). Gene counts
from RNAseq analysis of SHAM, AAV1-eGFP, and AAV1-MANF samples
were normalized with DESeq2 before running the analysis on GSEA
4.0.3 with 1000 permutations.
2.3. Proteomics
2.3.1. Sample preparation
20 μL of sample homogenate was used for proteomics. To solubilize
the proteins, 100 μL of 0.2% (w/v) RapiGest SF in 50 mmol/L ammo-
nium bicarbonate and 80 μL of 50 mmol/L ammonium bicarbonate
were added to the samples, followed by 15 min sonication and 5 min
heating to 99 °C with a heating block. Insoluble cell debris was removed
by two 15-min rounds of centrifugation at 20817 G at 25 °C. Total
protein content of the samples was determined using Thermo Pierce
BCA Protein Assay Kit and the results were measured with CLARIOstar
plate reader (BMG Labtech, Offenburg, Germany). The amount of
homogenate equivalent to 46.5 μg of total protein was taken for further
sample preparation and diluted to 200 μL with 0.1% (w/v) RapiGest SF
in 50 mmol/L ammonium bicarbonate.
Disulphide bonds were reduced with 22 μL of 50 mmol/L dithio-
threitol (final concentration 5 mmol/L) for 30 min at 56 °C and then
carbamidomethylated with 25 μL of 150 mmol/L iodoacetamide (final
concentration 15 mmol/L) for 30 min at room temperature and pro-
tected from light. Proteins were digested with 5 μL of 0.5 mg/mL se-
quencing grade modified trypsin overnight at 37 °C with shaking.
Following digestion, the samples were acidified with 19 μL of 10%
trifluoroacetic acid and the RapiGest SF was hydrolysed for 45 min at
37 °C, and consequently centrifuged for 10 min at 17949 G at 25 °C.
2.6 μL of acetonitrile was added to the samples, followed by purifica-
tion with C18 MicroSpin columns (The Nest Group Inc., Southborough,
MA, USA; SEM S118V) as previously described (Talman et al., 2018),
evaporation to dryness with a vacuum centrifuge, and storage at
−20 °C.
2.3.2. LC-MS analysis
Prior to LC-MS analysis, the samples were resolubilized in 30 μL of
0.1% trifluoroacetic acid, 1% acetonitrile in LC-MS grade water with
15 min sonication. The samples were analyzed in a randomized order,
each sample followed by one wash run, and a pooled quality control
(QC) sample was run at the beginning and the end of the sequence. The
LC-MS analysis was performed with EASY-nLC 1000 coupled to Q
Exactive mass spectrometer using Xcalibur version 3.1.66.10 (Thermo
Scientific). Tryptic peptide solution equivalent to ~4.5 μg of digested
protein (3.0 μL) was loaded onto Thermo Acclaim C18 columns (trap
column: PepMap 100, 75 μm × 2 cm, 3 μm, 164,946; analytical
column: PepMap RSLC, 75 μm × 15 cm, 2 μm, 164,940) and separated
Fig. 1. Experimental outline. Male Sprague Dawley
rats were subjected to 60 min cerebral ischemia or
sham operation, followed by viral vector injections
of MANF or eGFP 2 days post-stroke, and sampling of
the peri-infarct area 4 days post-stroke. Numbers (N)
correspond to animals used for proteomic and me-
tabolomic / transcriptomic analyses.
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using the following gradient: 5 min 5% eluent B, 120 min from 5 to 35%
eluent B, 5 min from 35 to 80% eluent B, and 1 min from 80 to 100%
eluent B, followed by 9 min column wash with 100% eluent B (A: 1%
acetonitrile, 0.1% formic acid 0.01% trifluoroacetic acid in LC-MS
grade water; B: 98% acetonitrile, 0.1% formic acid, 0.01% tri-
fluoroacetic acid in LC-MS grade water). For detection, top10 data-
dependent acquisition was applied, in which the 10 most intensive ions
from the MS1 full scan (200 to 2000 m/z, resolution 70,000) were
fragmented with collision-induced dissociation and analyzed in MS2
(isolation window 2 m/z, normalized collision energy 28, resolution
17,500). 30 s dynamic exclusion was applied.
2.3.3. Data processing
Protein identification (FDR < 0.01 on both peptide and protein
level) and quantification were done with Andromeda and MaxQuant
version 1.6.1.0 (Cox et al., 2011; Cox and Mann, 2008). Reviewed
Rattus norvegicus UniProtKB/Swiss-Prot (UniProt Consortium, 2019)
proteome (8023 entries, downloaded 2018-05-05), supplemented with
separate fasta files for contaminants (embedded in MaxQuant), human
MANF (accession P55145) and eGFP (accession C5MKY7), was used as
the database, and the search was done with mass tolerance of 4.5 ppm
in MS1 and 20 ppm in MS2. Protein quantification was done with un-
ique and razor peptides, and LFQ (label-free quantification) intensity
was used as a measure of protein abundance without further normal-
ization.
Downstream data analysis was performed with RStudio (RStudio
Team, 2019) version 1.1.456 running with R version 3.5.0 (R Core
Team, 2019). Decoy hits and proteins flagged as potential contaminants
were removed, excluding eGFP and porcine trypsin (accession P00761,
used for QC). For statistical testing, missing values were imputed with
normally distributed noise (mean = non-zero minimum for each pro-
tein divided by 10; sd = mean divided by 10). Protein LFQ intensities
were compared with one-way ANOVA, Tukey's HSD post-hoc tests, and
FDR multiple hypothesis correction; changes with q-value< 0.01 were
considered significant. The enrichment analysis of GO (The Gene
Ontology Consortium, 2019; 2017) terms and KEGG (Kanehisa and
Goto, 2000) pathways was performed with DAVID 6.8 (Huang et al.,
2009a, 2009b). For minimizing bias induced by the analytical method,
the list of all quantified proteins was used as the background. Un-
collapsed (ALL) GO terms were used. Trypsin, eGFP, and human MANF
were excluded from the enrichment analyses.
Quality control data for the proteomics analysis is in the supple-
mentary material. The data have been deposited in the MassIVE data
repository (http://massive.ucsd.edu/) under the accession number
MSV000083869.
2.4. Metabolomics
2.4.1. Extraction of metabolites
Extraction was performed for positive (POS) and negative ion mode
(NEG) MS measurements separately as follows: 20 μL of homogenate or
Milli-Q water (blanks, two for POS MS and three for NEG MS) was pi-
petted into an Eppendorf tube. 30 μL of Milli-Q water, 200 μL of me-
thanol, and 5 μL of internal standard (IS) mixture were added to the
tubes, and the tubes were vortexed. The POS MS IS mixture consisted of
4–20 μg/mL of d31-PC, d31-PG, lysoPC(17:0), 27-hydroxycholesterol-
d6, verapamil, propranolol, d4-lysine, palmitic acid-d31, ibuprofen, and
pregnenolone-d4, and the NEG MS IS mixture of 25 μM d31-PG, 500 μM
d4-lysine, and 500 μM palmitic acid-d31 in methanol. The tubes were
transferred to ice and the samples were incubated for 30 min.
Precipitate was removed by centrifugation at 12470 G for 5 min, and
the supernatants were transferred into deactivated vial inserts for sto-
rage in −20 °C. A QC sample was prepared by pooling 5 μL of each
sample extract.
2.4.2. LC-MS analyses
The analyses were performed with Thermo Dionex Ultimate 3000
UHPLC and Orbitrap Fusion mass spectrometer (Thermo Fisher
Scientific). 5 μL (POS MS) or 3 μL (NEG MS) of sample was injected into
a Waters Acquity BEH C18 column (2.1 × 100 mm, 1.7 μm particles)
equipped with an in-line filter. For POS MS analysis, we used a 15-min
linear gradient from 100% A to 100% B, followed by a 10-min isocratic
period of 100% B, and a 5 min equilibration to initial conditions (A:
0.1% formic acid and 5% methanol in MQ water; B: 0.1% formic acid in
methanol). Eluent flow rate was 0.30 mL/min. The column and auto-
sampler temperatures were maintained at 25 and 10 °C, respectively.
For NEG MS analysis, the separation was performed using a 3 min linear
gradient from 30% to 90% B, followed by 1 min linear gradient to 100%
B, 6 min isocratic period of 100% B, and 5 min equilibration to initial
conditions (A: 6/94/1 volumetric ratio of methanol, Milli-Q water, and
1 mol/L NH4COOH in Milli-Q water; B: 100/1 volumetric ratio of me-
thanol and 1 mol/L NH4COOH in MQ water). Eluent flow rate was
0.35 mL/min. The column and autosampler temperatures were main-
tained at 50 and 10 °C, respectively. Ionization was achieved with a
heated electrospray source using the following settings (POS/NEG MS):
spray voltage of 3.0/−1.9 kV, sheath gas 25/40 arbitrary units, aux-
iliary gas 10/12 arbitrary units, sweep gas 0/1 arbitrary units, ion
transfer tube temperature 333 °C, and vaporizer temperature 290/
317 °C. The data was collected in centroid mode. MS scans were per-
formed with the resolution of 120,000 FWHM. In POS MS, the Easy-IC
internal calibrant system of the MS instrument was used for internal
calibration with fluoranthene. In NEG MS, the internal calibration
system was not used. Data was collected at m/z range 100–1000 (POS
MS, NEG MS 2–15 min), except at 0–2 min in NEG MS analysis, where
m/z range 50–500 was collected in order to achieve sufficient sensi-
tivity for small metabolites. The run order of samples was randomized
except in the case of the QC sample and blanks. The QC sample was
injected 6 times: as the first and last sample of the series and evenly
distributed between samples. After initial data processing, MS/MS
spectra were collected for the annotation of features with the largest
fold changes (POS MS > 2, NEG MS > 1.5) and q < 0.01. For MS/
MS, the individual samples in each sample group were pooled, resulting
in one pooled sample per sample group. MS/MS data was acquired from
the pooled sample with the highest MS1 signal. Quadrupole isolation
window of 1, HCD fragmentation mode with energies of 25% and 40%
and mass resolution of 30,000 FWHM were used for the MS/MS ac-
quisitions.
2.4.3. Data processing
MzMine2 (Pluskal et al., 2010) was used for creating feature lists by
applying the following functions: mass detection (centroid algorithm),
chromatogram builder, chromatogram deconvolution (local minimum
search algorithm), deisotoping, alignment (join aligner algorithm), fil-
tering (number of found), gap filling, and filtering (duplicate filter). For
POS MS data, peak areas were normalized with the average of relative
responses of the internal standards d4-lysine, lysoPC(17:0), and d31-
PC. For NEG MS data, peak heights were used without correction.
Statistical tests were performed with RStudio (RStudio Team, 2019)
(version 1.0.136/1.0.383 (POS/NEG MS)), running with R version 3.2.2
(R Core Team, 2019). Fold change values were calculated, and differ-
ences between the sample groups were searched with two-sided Stu-
dent's t-test using Welch approximation. p-values were adjusted with
FDR correction (Benjamini and Hochberg). Features with q < 0.01 and
signal to noise> 5 in the upregulated group compared to blank samples
were considered to have a statistically significant difference between
the sample groups. Of these, features with fold change over 2 (POS MS)
or 1.5 (NEG MS) were annotated based on the average accurate mass of
the feature (from MzMine2 analysis) and by comparing the measured
MS/MS spectra against spectral databases or repositories mzCloud
(https://www.mzcloud.org/), NIST 2014 MS/MS (http://chemdata.
nist.gov/), HMDB (Wishart et al., 2018), and Metlin (Guijas et al.,
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2018). In addition, literature (Pulfer and Murphy, 2003), CSI:FingerID
(Dührkop et al., 2015; Shen et al., 2014), LipidMaps databases (Sud
et al., 2007), and known group-specific fragmentation of lipids and
phosphate groups containing species were used for the annotations.
Some features were annotated as adducts or fragments based on accu-
rate mass and retention time (and peak shape) matching that of a
corresponding feature annotated by MS/MS. For selected lipids with
corresponding accurate masses, same fatty acid composition was as-
sumed in POS MS to that observed in NEG MS.
Quality control data for the metabolomics analysis can be found in
the supplementary material.
2.5. Immunohistochemistry
Brain sections were deparaffinised and hydrated through xylenes
and graded ethanol series and subjected to heat-induced antigen re-
trieval with 0.01 mol/L citrate buffer (pH 6.0) for 40 min using a
steamer. For immunofluorescence, tissues were washed thoroughly
with PBS, permeabilized with PBS-Triton-X 0.3% (v/v) and blocked
with PBS-Triton-X 0.3% (v/v), 10% normal donkey serum. Next, tissues
were incubated with primary antibodies overnight at 4 °C, washed
thoroughly with PBS and incubated for 2 h with secondary antibodies.
Tissues were counterstained with DAPI. The following primary anti-
bodies were used sequentially: S100A9 (1/100; R&D systems, Cat#
AF2065; RRID:AB_2184263), IBA1 (1/250; Cat# 019–19,741,
RRID:AB_839504), donkey anti-goat 568 (Molecular Probes Cat# A-
11057, RRID:AB_142581) and goat anti-rabbit 488 (Thermo Fisher
Scientific Cat# A-11034, RRID:AB_2576217). Images were acquired
with a Zeiss LSM700 confocal laser scanning microscope. For DAB
staining and subsequent analysis, equivalent brain sections (number of
animals per genotype = 7, number of sections per animal = 4) were
deparaffinised and hydrated through xylenes and graded ethanol series
and subjected to heat-induced antigen retrieval with 0.01 mol/L citrate
buffer (pH 6.0) for 40 min using a steamer. Tissues were subsequently
treated with 0.5% H2O2 for quenching of endogenous peroxidase ac-
tivity for 30 min, washed with TBS, permeabilized with TBS-Triton-X
0.1% (v/v) and blocked with TBS-Triton-X 0.1% (v/v), 5% normal
rabbit serum. S100A9 (R&D systems; Cat# AF2065, RRID:AB_2184263)
primary antibody was diluted in blocking solution (1/1000) and tissues
were incubated overnight at 4 °C. Next, sections were washed thor-
oughly with TBS and treated with anti-goat biotinylated antibody and
avidin-biotin-peroxidase complex (PK-4005, Vector laboratories), and
DAB substrate (SK-4100, Vector laboratories), according to manufac-
turer's instructions. Images were captured with a Pannoramic 250
FLASH II digital slide scanner (3DHISTECH) equipped with a 4MP
CMOS camera. Images were analyzed using CaseViewer v.2.1 (3DHIS-
TECH). Statistical analysis was performed with GraphPad Prism 6.
Statistical analysis of the counts of S100A9-positive cells was done with
unpaired two-tailed t-test.
2.6. qPCR
For qPCR, punch samples were used from the same animals as for
proteomics and metabolomics, but using only 6 animals in the SHAM
group. RNA was extracted from punch-samples of tissue, taken from the
lateral peri-infarct cortex (AP level + 1 from a 1 mm coronal section
cut in a cryostat). RNA was extracted with Trizol reagent and treated
with DNase (Ambion; #1906). Total RNA concentration and quality
were determined with NanoDrop 1000 v3.7.1 and Agilent 2100
Bioanalyzer. cDNA synthesis was carried out using an oligo-T18 primer
and Maxima H minus reverse transcriptase (Thermo Fisher Scientific;
#EP0751). Real-time quantitative PCR (qPCR) was performed on a
Lightcycler®480 real-time PCR system (Roche Diagnostics) using
Lightcycler®480 SYBR Green I Master complemented with 2.5 pmol of
primers and cDNA corresponding to 10 ng of total RNA in the final
volume of 10 μl on 384-well plates. Reactions were performed in du-
plicate and analyzed with Lightcycler®480 Software. The length of re-
sulting PCR products was verified by agarose gel electrophoresis. Gene
expression was normalized to rat Hypoxanthine guanine phosphor-
ibosyl transferase 1 (Hprt1) expression level. Statistical comparison
between the sample groups was done using one-way ANOVA with
Tukey's multiple comparisons test. The primers are listed in Table 1.
3. Results
3.1. Transcriptomics
The peri-infarct region from rats subjected to stroke and treated
with AAV-MANF or AAV-eGFP, and from sham operated rats, was
analyzed (Fig. 1). We first carried out hierarchical clustering and
principal component analysis (PCA) of the transcriptomics data. The
SHAM group clearly separated from the stroke groups (AAV-eGFP and
AAV-MANF), and the AAV-eGFP and AAV-MANF groups were similar
(Fig. S2). One sample from the AAV-MANF group was characterized as
an outlier based on inter- and intra-cluster distances and removed from
the analysis. Altogether, 3347 genes were differentially expressed be-
tween the groups (q < 0.01, fold change> 2). The changes were re-
markable in the comparison of stroke groups to the SHAM group,
whereas there were only minor differences between the AAV-MANF and
AAV-eGFP groups (Fig. 2A). In stroke samples compared to SHAM,
more genes were upregulated than downregulated after stroke
(Fig. 2A). Highly similar sets of transcripts were upregulated in the
AAV-MANF and AAV-eGFP groups relative to the SHAM group, but the
overlap was smaller in the downregulated genes (Fig. 2B). When
comparing the AAV-MANF group to the AAV-eGFP group 77 genes were
upregulated and 2 genes were downregulated. The majority of the
differentially expressed genes were protein-coding (Fig. 2C). Enrich-
ment analysis showed upregulation of genes related to inflammation,
proliferation, apoptosis, and regeneration in the stroke groups relative
to the SHAM group (Data S1). The raw and size factor normalized
counts, ratios and q-values of the detected transcripts, the differentially
expressed transcripts in each comparison, and the results of the en-
richment analyses are listed in Data S1.
3.2. Proteomics
Altogether 2501 proteins were identified (FDR < 0.01 on peptide
and protein level) and quantified. With hierarchical clustering and PCA,
the SHAM samples were clearly distinguished from the other samples,
but no differences were found between the AAV-MANF and AAV-eGFP
groups (Fig. S3). Relative to the SHAM group, 308 (203 upregulated,
105 downregulated) and 213 (152 upregulated, 61 downregulated)
proteins were differentially expressed in AAV-eGFP and AAV-MANF
groups, respectively (q < 0.01, Fig. 3A and B). GO enrichment analysis
showed upregulation of proteins related to protein synthesis and
downregulation of neural proteins in both stroke groups relative to the
SHAM group (enrichment analysis, Data S2). There was a high overlap
between proteins differentially expressed in AAV-eGFP relative to
SHAM and AAV-MANF relative to SHAM, and the overlap of the up-
regulated proteins was higher than that of the downregulated (Fig. 3B),
as in transcriptomics. Only two proteins were significantly differentially
expressed between the AAV-MANF and AAV-eGFP groups: S100A8 and
S100A9 were downregulated in the AAV-MANF group (Fig. S4,
Table 1
Primers used for the qPCR.
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discussed in more detail in the MANF-induced changes). The LFQ in-
tensities (raw and zero-imputed), ratios, and q-values of all quantified
proteins, the differentially expressed proteins in each comparison, and
the results of the enrichment analysis are listed in Data S2.
3.3. Metabolomics
The positive (POS) and negative (NEG) ion mode metabolomics
analyses and data processing resulted in 7782 and 2001 features, re-
spectively (Data S3). In line with transcriptomics and proteomics, PCA
and hierarchical clustering of both the separate POS and NEG MS da-
tasets showed separation of the SHAM group from the stroke groups
(Figs. S5 and S6). The AAV-eGFP and AAV-MANF groups could not be
separated from each other.
In positive ion mode, 95 and 65 features were lower in intensity in
AAV-eGFP and AAV-MANF groups compared to SHAM, respectively,
while 375 (AAV-eGFP) and 93 (AAV-MANF) features were higher in
intensity (q < 0.01, fold change> 2, Fig. 4A). In negative ion mode,
46 and 27 features were lower in intensity in the AAV-eGFP and AAV-
MANF groups compared to the SHAM group, respectively, while 111
(AAV-eGFP) and 26 (AAV-MANF) features were higher in intensity
(q < 0.01, fold change> 1.5, Fig. 4B). Based on the MS/MS data and
database/literature comparisons of these features, 88 metabolites with
significantly different abundance between sample groups could be an-
notated (Fig. 4C and Data S3). Many of the annotated metabolites were
seen as several features (total of 163 features assigned to the 88 me-
tabolites) due to ionization in both POS and NEG MS, as well as in-
source formation of adducts and fragments. No statistically significant
differences were found between the AAV-eGFP and AAV-MANF groups,
but for multiple metabolites, the changes relative to the SHAM group
were significant in the AAV-eGFP group but not the AAV-MANF group.
The annotated metabolite data and the unannotated feature data are
listed in Data S3.
3.4. Stroke markers and transgene expression
Upregulation of the known stroke markers glial fibrillary acidic
protein (GFAP) and heat shock protein beta-1 (HSPB1) on transcript
and protein level was observed in both AAV-eGFP and AAV-MANF
groups relative to the SHAM group, confirming successful infarction in
the animals (Fig. 5A). In addition, the levels of acetylaspartic acid were
decreased in the stroke samples, indicating neuron loss or dysfunction
(Fig. 5B) (Demougeot et al., 2004; Moffett et al., 2007). As expected,
the AAV1-expressed human Manf (hManf) and eGFP transcripts were
heavily upregulated in the AAV-MANF and AAV-eGFP groups, respec-
tively, and the human MANF and eGFP proteins were only detected in
the corresponding groups (Figs. 5C and S7A).
Endogenous rat MANF protein was upregulated in the AAV-MANF
group with q < 0.01 and in the AAV-eGFP group with q = 0.019 by
about 2-fold relative to the SHAM group (Figs. 5C and S7A). MANF has
been reported to be upregulated after stroke (Shen et al., 2012; Yu
et al., 2010), but the slight difference in rat MANF levels observed
between AAV-eGFP and AAV-MANF can be accounted for by the similar
peptides in human and rat MANF (Fig. S7B; see the supplementary
material for a detailed description). The levels of rat Manf transcript
showed a trend towards upregulation in the stroke samples, but did not
reach the significance criteria between the sham and stroke groups nor
in the AAV-eGFP and AAV-MANF groups (Fig. 5C and S7A).
3.5. Stroke-induced changes
Next, the stroke-induced changes detected in the AAV-eGFP and/or
AAV-MANF groups relative to the SHAM group were analyzed, char-
acterizing the molecular profile of the post-stroke peri-infarct region.
Fig. 2. A: Numbers of differentially regulated transcripts between the groups show major changes between the SHAM group and the AAV-eGFP or AAV-MANF
groups, but minor changes between the AAV-eGFP and AAV-MANF groups. B: The ones upregulated are on the left and the ones downregulated are on the right C:
Most of the transcriptomic changes occurred in protein-coding genes; gene type annotation according to NCBI Gene database (Brown et al., 2015), with the addition
of AAV-expressed eGFP and hMANF to “others”. A to C: criteria for significance were q < 0.01 and fold change> 2. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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There was a remarkable overlap between the changes in the AAV-eGFP
and AAV-MANF treated animals relative to SHAM (Figs. 2B, 3B, 4A, B),
but relative to SHAM, there were multiple changes in the AAV-eGFP
group that were not significant in the AAV-MANF group (Figs. 2A, 3A,
4C).
3.5.1. Energy metabolism
The levels of saccharides and sugar phosphates were increased in
the stroke groups relative to the SHAM group, although for some sac-
charide species the increase in the AAV-MANF group was not statisti-
cally significant (Fig. 6A). On the proteomic level, no significant en-
richment of energy metabolism-related pathways was observed, and the
levels of enzymes catalyzing the rate-limiting steps of the KEGG path-
ways glycolysis/gluconeogenesis (rno00010), citrate cycle (rno00020),
and oxidative phosphorylation (rno00190) were unchanged. On the
transcriptomic level, no genes related to these three pathways changed
significantly in expression. The proteins 6-phosphogluconate dehy-
drogenase, decarboxylating (PGD), and transaldolase (TALDO1), and
the transcripts Pgd, deoxyribose-phosphate aldolase (Dera), and glu-
cose-6-phosphate dehydrogenase (G6pd), in the pentose phosphate
pathway (KEGG: rno00030), were upregulated in AAV-eGFP and/or
AAV-MANF groups relative to the SHAM group (Fig. S8A), but no
overall activation of the pentose phosphate pathway was observed.
3.5.2. Purine metabolism
In the metabolomics data, the levels of the purines adenine and
hypoxanthine, and purine nucleosides adenosine and guanosine were
decreased in the stroke groups relative to the SHAM group (Fig. 6B).
Adenosine was significantly decreased in the AAV-eGFP group but did
not reach statistical significance in the AAV-MANF group. A similar
trend was found with guanine as well, although based on the metabo-
lomics data, guanine can not be differentiated from a mass spectro-
metric fragment of guanosine. In contrast, the levels of the end product
of purine degradation, uric acid, were increased in the AAV-eGFP group
relative to the SHAM group, and the difference between the AAV-MANF
and SHAM groups was not statistically significant. In line with this, the
enzymes catalyzing the degradation of purines (Fig. 6B) were upregu-
lated after stroke in the proteomics and/or the transcriptomics data
(Fig. 6C). Other detected proteins than purine nucleoside phosphor-
ylase (PNP) on the purine metabolism pathway (KEGG: rno00230) did
not change in abundance, but some changes were observed in the
transcriptomics data, mostly upregulation in the sample groups sub-
jected to stroke (Fig. S8B). The decreasing nucleotide concentrations
after stroke have been linked to reduced glucose-6-phosphate dehy-
drogenase activity (Irie et al., 2014), but in our data, the G6pd tran-
script was upregulated in AAV-eGFP group relative to SHAM, and the
G6PDX protein showed no differences between the sample groups (Fig.
S9B).
Fig. 3. A: Dual volcano plot showing the log2 fold changes and -log10 q-values of proteins in AAV-MANF/SHAM and AAV-eGFP/SHAM comparisons, calculated from
the proteins' LFQ intensities. Overall, there are more changes, and the changes are larger and more significant, in the AAV-eGFP/SHAM comparison than in the AAV-
MANF/SHAM comparison. Significantly upregulated and downregulated proteins are shown in colors. B: Venn diagrams showing the numbers of differentially
expressed proteins in AAV-eGFP/SHAM and AAV-MANF/SHAM comparisons (q < 0.01; no fold change filtering), indicating higher overlap in the upregulated than
in the downregulated proteins.
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3.5.3. Glutamatergic signaling
Glutamate-mediated excitotoxicity plays a major role in stroke (Lai
et al., 2014), but as expected for samples collected 4 days post-stroke
(Guyot et al., 2001), no change in glutamate levels was observed in the
metabolomics data. No enrichment of genes related to glutamatergic
signaling was observed in transcriptomics or proteomics (Data S1 and
S2). However, glutamine synthetase (GLUL), the enzyme converting
glutamate into glutamine, was upregulated in the stroke groups relative
to the SHAM group (Fig. S8C). Also, aspartate aminotransferase, cyto-
plasmic (GOT1), the enzyme that biosynthesizes glutamate and ox-
aloacetate from 2-oxoglutarate and aspartate, was downregulated (Fig.
S8C). The corresponding transcripts followed a similar pattern as the
proteins, but their fold changes were below 2. The aforementioned
metabolites, tentatively identified by exact mass, did not differ sig-
nificantly between the sample groups and thus were not subjected to
MS/MS for identification.
3.5.4. ER stress and unfolded protein response
Increased abundance of endoplasmic reticulum (ER) chaperone BiP
(HSPA5) protein, and protein disulfide-isomerase (P4HB) protein and
transcript, was observed in the stroke groups relative to the SHAM
group (Fig. 7A), indicative of ER stress and the unfolded protein re-
sponse (UPR). In line with this, an upregulation of proteins related to
protein synthesis was observed in the stroke groups relative to the
SHAM group (enrichment analysis, Data S2), but such enrichment of
protein synthesis-related genes was not observed in the transcriptomics
data.
3.5.5. Apoptosis/immune cells related markers
In the AAV-MANF and AAV-eGFP groups, we found upregulation of
apoptosis regulator BAX in the proteomics data, BH3-interacting do-
main death agonist (Bid) in the transcriptomics data, and cathepsin D
(CTSD) in both proteomics and transcriptomics data, because of im-
mune cell infiltration (Fig. 7B). Also, the transcriptomics data showed
an upregulation of genes related to NF-κB signaling in the stroke groups
relative to SHAM (Data S1). Also, some transcripts of NF-κB subunits
and NF-κB inhibiting proteins were upregulated (Fig. S9A), whereas the
proteins were not detected. These changes are likely related to changes
in cell type composition e.g. infiltration of immune cells after stroke.
Furthermore, we detected upregulation of several caspase transcripts
(Fig. S9B) and the enrichment of transcripts related to apoptosis (Data
S1) in the stroke samples. Ceramides and other sphingolipids are known
Fig. 4. (previous page). A and B: Venn diagrams showing the numbers of metabolomic LC-MS features of significantly different abundance in AAV-eGFP/SHAM and
AAV-MANF/SHAM comparisons in positive (A) and negative (B) ion mode (q < 0.01; fold change> 2 in positive ion mode,> 1.5 in negative ion mode). C:
Heatmap of the identified metabolites' relative signal across the samples.
Fig. 5. A: Expression of the stroke markers GFAP and HSPB1, on protein (boxplots) and transcript (heatmap) levels, was increased in the sample groups subjected to
stroke, confirming the validity of the dMCAo stroke model. B: Intensities of acetylaspartic acid decreased in sample groups subjected to stroke, indicating loss or
dysfunction of neurons. C: Expression of the AAV1-expressed human MANF (hManf), enhanced green fluorescent protein (eGFP), and endogenous rat MANF (rManf),
on protein (boxplots) and transcript (heatmap) levels. Increased transcript and protein abundance of the transgenes indicates successful transduction. Note that the
eGFP protein appears to be significantly upregulated in the AAV-eGFP group compared to the SHAM group but not to the AAV-MANF group, although it was detected
in neither the SHAM nor the AAV-MANF group; this is because in the FDR multiple hypothesis correction, the outcome q-values are affected not only by the number
of statistical tests done, but also by the distribution of all uncorrected p-values (Benjamini and Hochberg, 1995). Asterisks indicate statistically significant differences
in proteomics and metabolomics, and genes that were statistically significantly differentially expressed between any of the sample groups in transcriptomics. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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to play a role in apoptosis (Taha et al., 2006), and in line with this, the
metabolomics data showed approximately 2-fold increase of ceramide
(d18:1/16:0) and ceramide(d18:2/16:0) in the AAV-eGFP group com-
pared to the SHAM group, while for the AAV-MANF group there was a
smaller increase and the q-value did not reach the<0.01 level
(Fig. 7C). Also, sphingosine and phytosphingosine (Fig. S9C), as well as
the corresponding sphingomyelins (Fig. S9D) were increased in abun-
dance in the AAV-eGFP group relative to the SHAM group. The tran-
scriptomics data showed increased expression of several genes related
to sphingolipid metabolism in the stroke groups relative to the SHAM
group, but no significant changes in the detected corresponding pro-
teins were seen (Fig. S9E). Changes in the levels of sphingosine-1-
phosphate receptors were observed both in proteomics and tran-
scriptomics (Fig. S9F), as another indication of infiltrating immune cells
(Weigert et al., 2019).
3.5.6. Phospholipase A2 activation
One of the most prominent metabolic changes occurring after stroke
Fig. 6. A: Intensities of the detected saccharides and sugar phosphates increased in sample groups subjected to stroke. B: Part of the purine metabolism pathway and
the intensities of the detected metabolites on the pathway, showing decrease of purine degradation reaction intermediates and accumulation of the end product,
urate. C: Expression of the genes associated with the pathway part shown in panel B on protein (boxplots) and transcript (heatmap) levels, indicating activated purine
metabolism.
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was the increase of free, long-chain unsaturated fatty acids; in most
cases, the increase was significant in the AAV-eGFP but not in the AAV-
MANF group (Fig. 7D). Acylcarnitines, the carnitine conjugates of fatty
acids that enable the transport of fatty acids into mitochondria (Longo
et al., 2016) and are potential stroke biomarkers (Seo et al., 2018),
followed a similar pattern (Fig. S10A). In addition, a higher abundance
of several lysophosphatidylcholine (lysoPC) and lysophosphatidylserine
(lysoPS) lipid species were detected in the AAV-eGFP group than in the
SHAM group; for the AAV-MANF group, the trend was similar, but the
difference to the SHAM group did not reach statistical significance
(Fig. 7E). The opposite behavior was observed for some lysopho-
sphatidylinositol (lysoPI) and lysophosphatidylglycerol (lysoPG) lipid
Fig. 7. A: Expression of ER stress markers HSPA5 and P4HB on protein (boxplots) and/or transcript (heatmap) levels increased after stroke. B: Increased expression
Bax, Bid, and Ctsd on protein (boxplots) and/or transcript (heatmap) levels indicates infiltration of immune cells in the sample groups subjected to stroke. C to E: The
intensities of certain ceramides (C), free fatty acids (D), and lysophosphatidylcholine and lysophosphatidylserine (lysoPC and lysoPS, respectively; E) lipid species
were significantly increased in the AAV-eGFP but not in the AAV-MANF group relative to SHAM. F: In the sample groups subjected to stroke, the expression of three
different phospholipase A2 transcripts increased.
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species (Fig. S10B). Also, some phospholipid species decreased and
others increased in abundance after stroke (Data S3), but our data does
not show any systematic statistically significant decrease of certain
phospholipid types (annotated by accurate mass only). hHowever, the
trend was towards lower abundance in the stroke samples for most
phosphatidylcholines, phosphatidylethanolamines, phosphatidylser-
ines, and phosphatidylinositols.
Both free fatty acids and lysolipid species are cleaved from phos-
pholipids by cytosolic phospholipase A2 (cPLA2). The transcriptomics
data showed an upregulation of three PLA2 genes after stroke: Pla2g2d,
Pla2g4a, and Pla2g7 (phospholipase A2, groups IID, IVA, and VII, re-
spectively; Fig. 7F), but no enrichment of GO terms related to PLA2
(Data S1). In the proteomics data, none of the PLA2s were detected, but
peroxiredoxin 6 (PRDX6), which in addition to its peroxidase activity
displays calcium-independent PLA2 (iPLA2) activity, was slightly
downregulated in the AAV-MANF group but not in the AAV-eGFP group
relative to the SHAM group (Fig. S10C). PRDX6 overexpression down-
regulates TLR4 (Yeo et al., 2019), and in line with this, our tran-
scriptomics data shows upregulation of Tlr4 (Fig. S10C) and genes re-
lated to TLR signaling (enrichment analysis, Data S1) in the sample
groups subjected to stroke. Furthermore, the proteomics data showed
the upregulation of PLA2 inhibiting proteins annexins A1 (ANXA1) and
A5 (ANXA5) in the AAV-eGFP group and annexin A3 (ANXA3) in both
the stroke groups relative to the SHAM group (Fig. S10D). In the
transcriptomics data, annexins A1 to A5 were upregulated in the sample
groups subjected to stroke.
3.6. MANF-induced changes
The MANF-induced changes detected between the AAV-eGFP and
AAV-MANF groups are presented below, characterizing the effect of
MANF treatment on the post-stroke peri-infarct region.
3.6.1. Response to virus
In transcriptomics data, 25 out of the 77 genes upregulated in the
AAV-MANF group relative to the AAV-eGFP group were associated with
GO terms indicating a response to the virus (Fig. 8A and B). Most of
these genes were also upregulated in the AAV-eGFP group relative to
the SHAM group (Data S1), but the upregulation was more pronounced
in the AAV-MANF group. Of the proteins encoded by these genes, three
were detected: interferon-induced GTP-binding proteins Mx1 and Mx2
(MX1 and MX2), and 2′-5′-oligoadenylate synthase 1A (OAS1A). MX1
was upregulated in the AAV-MANF group relative to the SHAM group,
but no other changes were significant, although the trend was similar as
in the transcriptomics data (Fig. 8C).
As MANF treatment seemed to modify the immune response to-
wards the virus, we compared our data to a previous data set in which
the transduction was done using AAV7 instead of AAV1 (Mätlik et al.,
2018). In the stroke groups relative to SHAM, the changes in AAV7-
transduced animals resembled those observed with AAV1, but in the
AAV7-MANF to AAV7-eGFP comparison, no changes in response to
virus-related transcripts was detected (Fig. 8D, Data S1). In the group-
wise comparison between animals from the AAV1-treated and AAV7-
treated sample sets, GO terms indicating a response to the virus were
enriched only in the genes upregulated in AAV1-MANF relative to
AAV7-MANF (Fig. 8E, Data S1), indicating a serotype-specific effect. In
contrast, in the genes differentially expressed between the eGFP groups
or the SHAM groups from these two sample sets, GO terms related to
ribosome and protein synthesis were enriched.
We wanted to see whether the differences in gene expression point
to a specific change in cell composition of the peri-infarct area after
AAV1-MANF treatment. We performed Gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) to see whether there is a systematic
change in the expression of genes that are expressed selectively or more
highly in major brain cell types and blood-derived immune cells. As
expected, compared to Sham-lesioned rats, the peri-infarct area of
AAV1-GFP injected animals that had undergone dMCAo contained
higher levels of mRNAs that are highly expressed in microglia and
peripheral immune cells (Table S6A). Comparison of AAV1-MANF and
AAV1-GFP-injected groups did not point to a clear change in cellular
composition of the peri-infarct area (Table S6B).
3.6.2. Phagocyte recruitment
The proteins S100A8 and S100A9 that are highly expressed in
macrophages and in neutrophils (Yui et al., 2003), were strikingly up-
regulated after stroke, but the effect was reversed by MANF expression
(Figs. 9A and S4); these two proteins comprised the only proteins be-
tween the AAV-MANF and AAV-eGFP groups that reached the set cri-
terion for statistical significance (q < 0.01). On the transcript level,
the trend was similar: S100a8 and S100a9 were upregulated in the
groups subjected to stroke, with more pronounced upregulation in the
AAV-eGFP group than in the AAV-MANF group, but the difference be-
tween these two groups was not significant (Figs. 9B and S4). S100A8
and S100A9 induce proinflammatory cytokines via TLR4 and NF-κB,
(Vogl et al., 2007), but in the transcriptomics data, genes related to
these processes were upregulated in both stroke groups relative to
SHAM, without any systematic difference between the AAV-MANF and
AAV-eGFP groups (enrichment analysis, Data S1).
To further characterize the role of S100A8 and S100A9 in the peri-
infarct region, we performed qPCR and immunohistochemistry. With
qPCR, upregulation of the S100a8 and S100a9 transcripts was detected
in the AAV-eGFP group but not the AAV-MANF group relative to SHAM
(Fig. 9C). With immunohistochemistry, we were able to identify
S100A9/IBA1 positive cells in the ipsilateral hemisphere in the stroke
core and in the peri-infract area of animals treated with AAV7-MANF
two days post-stroke (Fig. 9D and E). These cells were of amoeboid
morphology and contained multiple nuclei (Fig. 9D, arrows), the latter
being a feature of neutrophils and not of microglia. We also counted the
number of S100A9-positive cells in the peri-infract area of animals
subjected to stroke and subsequently treated with AAV7-GFP and
AAV7-MANF, but no significant difference was observed (Fig. 9E and
F).
4. Discussion
In this work, we characterized the transcriptomic, proteomic, and
metabolomic fingerprint for the peri-infarct region four days after is-
chemic stroke in comparison to sham-operated rats. In addition, we
investigated the molecular signature of post-stroke AAV-MANF treat-
ment with AAV-eGFP as the control. We utilized a multiomics ap-
proach, in which the different omics techniques produce com-
plementary information for a comprehensive picture. While
transcriptomics provides a global picture of the mRNA levels, it misses
the regulation of translation and variable protein turnover rates. Thus,
protein abundance cannot be directly inferred from transcript abun-
dance. On the other hand, both proteomics and metabolomics are
biased towards molecules that are readily detectable with the liquid
chromatography-mass spectrometry (LC-MS) instrumentation and the
sample preparation methods used. Despite the high sensitivity of these
instruments, many low-abundance proteins and metabolites are diffi-
cult to detect.
We identified both stroke-induced and MANF-induced changes in
the peri-infarct region. Stroke caused changes related to metabolism
and accumulation of sugars and sugar phosphates and purine de-
gradation was increased. As expected, we detected markers of increased
inflammation, ER stress, and apoptosis, as well as increased levels of
various lipid classes, including free fatty acids, acylcarnitines, most
sphingolipids, and some lysolipids. While the stroke-induced changes
were remarkable, we did not find metabolomic changes induced by
MANF, and the transcriptomic and proteomic changes were subtle. In
an AAV1 vector, but not an AAV7 vector, MANF increased the ex-
pression of a number of genes related to defense response to a virus. We
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do not know why the AAV1 serotype combined with MANF caused this
effect, while the GFP transgene did not. The difference may be due to
tropism, and different serotypes may express MANF in different cell
types and thereby contribute to a difference in the molecular changes.
There may also be a difference in the transduction efficiency despite
equivalent viral titers being injected into the brain. This would result in
different effective doses of MANF to the brain. Additional studies be-
yond the scope of this investigation are needed to identify the reasons
and one likely difference is the infiltration of inflammatory cells.
Importantly, MANF reversed the stroke-induced upregulation of the
Fig. 8. A: GO terms and KEGG pathways associated with immune response, especially to the virus, were significantly enriched in the genes upregulated in the AAV-
MANF group relative to the AAV-eGFP group in transcriptomics. B and C: Expression of genes associated with defense response against virus on transcript (B) and
protein (C) levels. Genes upregulated in the AAV-MANF group relative to the AAV-eGFP group in transcriptomics are shown. Asterisks indicate statistically significant
differences in proteomics and metabolomics, and genes that were statistically significantly differentially expressed between any of the sample groups in tran-
scriptomics. D: Summary of the transcriptomics changes detected when using AAV7 instead of AAV1 in a similar experimental design as described in Fig. 1. E:
Summary of the transcriptomics changes detected between the animals treated with AAV1 and AAV7.
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phagocyte proteins S100A8 and S100A9. The effect was validated on
the transcript level with qPCR, and with immunohistochemistry where
S100A9 was mapped to cells with the morphology of neutrophils.
In ischemic stroke, the oxygen and glucose deprivation leads to an
energy failure that induces widespread effects in the tissue. As no
changes in the expression of energy metabolic enzymes were detected
in our data, the increased levels of saccharides and sugar phosphates in
the stroke samples (Fig. 6A) may suggest attenuation of energy meta-
bolism and the consequent accumulation of upstream energy metabo-
lism precursors. Pentose phosphate pathway activation during cerebral
ischemia has been reported (Imahori et al., 2017), but our data suggests
that the activation is resolved by four days post-stroke (Fig. S8A).
Activation of purine degradation after stroke was observed in all
omics levels (Fig. 6B and C). In hypoxic conditions, ATP
Fig. 9. A and B: Increased expression of proteins (A) and transcripts (B) of S100A8 and S100A9 after stroke is partially reversed by MANF treatment. C: qPCR of
S100a8 and S100a9 transcripts shows similar changes as detected with proteomics and RNA sequencing (mean ± s.e.m., one-way ANOVA with Tukey's multiple
comparisons test). D: S100A9-positive cells are detected in the ipsilateral side of 4-day post-stroke rats treated with AAV7-MANF. These cells are also positive for the
myeloid marker IBA1 and contain multiple nuclei (arrows). White squares (top right) correspond to magnification of white squares at the left side of image. Scale
bars, 50 μm. E: S100A9-positive cells are found both inside the ischemic core and in the peri-infarct area of both AAV7-eGFP and AAV7-MANF treated animals. Scale
bars, 2000 μm. F: Statistical analysis of S100A9-positive cells found in the peri-infract area of AAV7-eGFP and AAV7-MANF treated animals (mean ± s.e.m.,
unpaired two-tailed t-test).
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dephosphorylation into adenosine continues and, at the same time,
adenosine kinase is not able to compensate for the loss of ATP. Thus,
intracellular levels of adenosine increase, resulting in its release into the
extracellular space (Van Wylen et al., 1986) and/or catabolism. ATP is
replenished by recirculation at reoxygenation, and adenosine levels of
the cerebral interstitial fluid decrease to baseline within 20 min after
the hypoxic incident. Similar release of guanosine has also been re-
ported, although the degradation of guanosine is not as rapid as that for
adenosine, and guanosine levels in the ischemic tissue have been found
to be increased at 7 days after ischemia but decrease to normal levels by
21 days after ischemia (Uemura et al., 1991). In our data, the levels of
adenosine and guanosine in the peri-infarct region tissue were de-
creased from the baseline (SHAM group) 4 days post-stroke (AAV-eGFP
and AAV-MANF groups) (Fig. 6B). This appears to be in disagreement
with the cited report, in which guanosine levels were increased at
7 days post-stroke (Uemura et al., 1991); however, in that study, the
infarct volume was sampled, whereas ours concentrated on the peri-
infarct region. On the other hand, the accumulation of uric acid is in
line with our results (Fig. 6B). Uric acid appears to play a role in stroke,
although its exact function in stroke is unclear (Pello et al., 2009).
A similar observation of decreasing nucleotide concentration has
been reported before (Irie et al., 2014), and it was suggested that this
may be due to the reduced activity of glucose-6-phosphate dehy-
drogenase (G6pd or G6PDX) in the pentose phosphate pathway. Our
data does not support this, as this enzyme showed a trend towards
upregulation in the stroke samples (Fig. S8A). However, the activity of
the human homologue of G6PDX is controlled by N-acetylation (Wang
et al., 2014), and if this applies to the rat homologue as well, abundance
alone is not sufficient to explain the potential changes in G6PDX ac-
tivity. Protein N-acetylation was not investigated in our study. Im-
portantly, the dual-function enzyme xanthine dehydrogenase/oxidase
(XDH), that catalyzes the reaction in which hypoxanthine is trans-
formed into xanthine and further into uric acid, has been reported to be
converted into its reactive oxygen species-producing oxidase form
during ischemia (Kinuta et al., 1989), and may be involved with the
oxidative damage to the ischemic tissue.
The UPR is a protective mechanism for cells against increased
misfolding of proteins in the lumen of the ER (Oslowski and Urano,
2011). In the stroke groups, we detected an increase of ER stress mar-
kers in the transcriptomic and proteomic data (Fig. 7A) whereas MANF
levels were increased only at the protein level. However, we did not
observe an increase in the common markers of the three UPR arms e.g.
sXbp1, ATF6 or ATF4, although MANF protein levels have been shown
to be increased by various ER stressors. It has been indicated that ER
stress is associated with ischemia (Hadley et al., 2018; Yang and
Paschen, 2016) and ER stress can be activated by oxidative stress,
characteristic of the ischemia/reperfusion of the dMCAo stroke model,
and ER stress and oxidative stress act in synergy and potentiate each
other (Nakka et al., 2016). However, we measured the levels at day four
post-stroke, indicating that global ER stress is transient. MANF plays a
role in the UPR, as evidenced by the activation of the UPR in MANF
knockout models, its protective effect against ER stress-induced cell
death, and its upregulation and secretion in ER stress (Apostolou et al.,
2008; Lindahl et al., 2014; Tseng et al., 2017). MANF-induced changes
related to the UPR or ER stress were not detected in our study, but that
could be related to time-dependent changes in the UPR following stroke
(Morimoto et al., 2007).
Although apoptotic cell death has been reported to cease by 2 days
post-stroke at the cellular level (Li et al., 2000; Liu et al., 2009; Mulcahy
et al., 2003), our data indicate increase in markers of apoptotic activity
still at 4 days post-stroke. We found increased expression of Ctsd, Bid,
and Bax proteins/transcripts, and caspase upregulation (Fig. 7B, C, and
S9B, respectively). Although these are associated with apoptosis they
can also have other functions in the cells, e.g. caspases and BAX have
been shown to be involved in long-term depression (Jiao and Li, 2011),
caspases are activated in myeloid cells after stroke (Rodhe et al., 2016).
Cathepsin-D is a protease enzyme that is active in lysosomes, and Ctsd
and Bid are rather specific for microglia/macrophages. Several studies
have previously reported increase of ceramides in stroke (Yu et al.,
2007), and ceramides, specifically ceramide (16:0), have been found to
induce apoptosis in several different types of stress models (Taha et al.,
2006). The route of accumulation of ceramide in stroke is unclear, since
evidence of both de novo synthesis and breakdown of sphingomyelin
has been found, and our data on this is inconclusive: upstream com-
ponents of ceramide biosynthesis were not detected, sphingomyelins
followed a similar abundance pattern as ceramides (Fig. S9D), and the
enzymes catalyzing the ceramide-producing reactions retained constant
levels. Also, the upregulation of Ctsd, Bid, and Bax transcripts and/or
proteins points towards lysosomal degradation and extracellular re-
ceptor activation as initiators of ceramide-related apoptotic events
(Kashkar et al., 2005). In these pathways, sphingomyelinases produce
ceramide that activates CTSD, which in turn activates BID that acts on
BAX.
Notably, for ceramides, sphingosine and phytosphingosine, and the
corresponding sphingomyelins (Figs. 7C, S9C, and S9D, respectively),
the abundance increase relative to SHAM was significant in the AAV-
eGFP group but not the AAV-MANF group, possibly pointing towards a
MANF-induced effect that was too small or variable to reach statistical
significance. A similar trend also applied to free fatty acids and lysoPC
and lysoPS lipid species (Fig. 7D and E), of which the lysoPSs have
immunomodulatory roles (Frasch and Bratton, 2012; Kamat et al.,
2015). Previous work has found free fatty acids, including arachidonic
acid (ArAc, FA(20:4)), to be increased in the early stage of ischemia/
reperfusion (Narita et al., 2000; Yang et al., 2017; Yoshida et al., 1980),
but the levels seem to return to baseline after 2–6 h after the onset of
MCAO. Increase of docosahexaenoic acid (DHA, FA(22:6)) occurs later
and its levels are above baseline at least a day after the MCAO onset
(Narita et al., 2000; Yang et al., 2017). Our data is in agreement with
these findings, as at the studied day 4 time point FA(22:6) was up over
2-fold (Fig. 7D), but FA(20:4) was increased only by approximately
20% after stroke without statistical significance (data not shown).
The origin for the increase of the free fatty acids and lysolipids in
the brain after stroke is unclear. One possible explanation is PLA2 that
catalyzes the production of free fatty acids and lysophospholipids by
cleaving fatty acids from the sn-2 position of various phospholipids. The
increased free fatty acid, lysoPC, and lysoPS abundance, together with
the trend towards decreased abundance of most phospholipids, suggests
that the free fatty acids originate from phosphatidylcholine (PC) and
phosphatidylserine (PS) lipid species (Fig. 7D and E). The exact sub-
types of activated PLA2s have not been confirmed, leaving some un-
certainty of the cleaved phospholipid classes. The increased abundance
of Pla2g2d, Pla2g4a, and Pla2g7 transcripts (Fig. 7F) suggests increased
expression of these subtypes, but cannot be confirmed, since none of the
PLA2 proteins were detected. PLA2 activation that results from the
calcium influx occurring at the onset of ischemia is a well-reported
phenomenon (Adibhatla et al., 2006). In addition, the calcium influx
promotes ER stress (Krebs et al., 2015) and can trigger calcium release
from the ER (Bootman et al., 2002), which may potentiate or prolong
the PLA2 activity. It is possible that the PRDX6 downregulation (al-
though the PLA2 activity of PRDX6 is calcium-independent; Fig. S10C)
and upregulation of PLA2-inhibiting annexins (Fig. S10D) observed in
our data represent a negative feedback-type PLA2 silencing function
which is activated as a response to stroke and remains active at least
4 days post-stroke. Notably, the iPLA2 activity of PRDX6 mediates in-
flammation in cerebral ischemia/reperfusion (Shanshan et al., 2017).
It is also possible that the free fatty acids originate from circulation.
Since the blood-brain barrier is known to be damaged in ischemia and
thus permeate serum albumin (Abdullahi et al., 2018; Merali et al.,
2017), the increase of free fatty acids may be due to albumin-bound
fatty acids. Indeed, many of the free fatty acids, as well as various other
lipid species, had moderate to high correlation with albumin. Notably,
intravenously administered albumin-bound FA(22:6) has been shown to
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be neuroprotective after stroke (Eady et al., 2014; Eady et al., 2012). In
hemorrhagic stroke, MANF has been suggested to mediate its neuro-
protective effects partially by defending the blood-brain barrier in-
tegrity (Li et al., 2019), but our data shows no evidence of this, likely
because of the late administration of MANF: there was no difference in
the albumin levels between the AAV-MANF and AAV-eGFP groups,
indicating no difference in blood-brain barrier permeability (Fig. S1A).
Compared to the stroke-induced changes, the changes due to MANF
treatment were more subtle. In transcriptomics, we detected increased
immune response towards the virus in the AAV-MANF group relative to
the AAV-eGFP group (Fig. 8A and B). Stroke itself is characterized by
remarkable inflammation (Anrather and Iadecola, 2016), but these re-
sults suggest that MANF may modulate response to a virus or increase
infiltration of immune cells. Interestingly, such differences in immune
response towardsthe virus were not observed when the transcriptomics
experiment was performed using AAV7 instead of AAV1, indicating that
the phenomenon may be specific for serotype 1 (Fig. 8D). Different AAV
serotypes have different tissue transduction capabilities and lead to
different expression levels in different time frames (Zincarelli et al.,
2008), which could explain the differences in the response, but this
requires further investigation. Many of the genes upregulated in the
AAV-MANF group compared to the AAV-eGFP group are associated
with defense response to (double-stranded) RNA viruses, whereas the
AAV genome in our vectors consists of double-stranded DNA. Thus, it is
possible that the changes are virus-independent. Traditionally, AAVs
have been considered to be of low immunogenicity (Zaiss and Muruve,
2005), which makes it surprising that the differences can be seen de-
spite the inflammation and other changes induced by stroke.
Regardless of the cause of the changes, in light of these results
parenchymal MANF appears to have immunomodulatory effects, which
is in line with previous research (Mätlik et al., 2018; Neves et al., 2016;
Hartman et al., 2019). According to our results, MANF reverses the
stroke-induced upregulation of the proteins S100A8 and S100A9
(Fig. 9A), further evidencing the immunomodulation by MANF. RNA
sequencing (Fig. 9B) and qPCR (Fig. 9C) of S100a8 and S100a9 tran-
scripts pointed towards the same direction, albeit without statistical
significance. S100A8 and S100A9 form a heterodimer calprotectin, but
have independent functions as well (Donato et al., 2013). They are well-
characterized as a damage-associated molecular pattern (DAMP) in the
CNS (Rayasam et al., 2018), involved in phagocyte recruitment and
released from phagocytes during activation (Frosch et al., 2000;
Rammes et al., 1997). S100A8 and S100A9 have been shown to be
induced in the peri-infarct region by focal cerebral ischemia and med-
iate central nervous system injury via inflammation (Ziegler et al.,
2009). Acting as activators of TLR4 (Vogl et al., 2007), they induce
proinflammatory cytokines such as TNF-α and IL-8 via NF-κB activa-
tion. Notably, these proteins share common mechanisms with some of
the stroke-induced changes presented earlier: lysoPC (Fig. 7E) produced
by cytosolic phospholipase A2 (cPLA2) has been shown to be a signal for
phagocyte recruitment in the mouse brain (Zhang et al., 2007), and
recent evidence suggests that PRDX6 (Fig. S10C) overexpression
downregulates TLR4, the target of S100A8/9, leading to decreased
neurogenesis in neural stem cell cultures (Yeo et al., 2019).
With immunohistochemistry, we were able to identify S100A9+
cells with neutrophil-like morphology in the peri-infarct region
(Fig. 9D). Furthermore, even though the AAV1-MANF treatment affects
the levels of S100A8 and S100A9 (Fig. 9A), the number of S100A9+
cells in the peri-infarct region was unaffected by AAV7-MANF (Fig. 9E
and F). The events occurring in the brain after stroke are characterized
by recruitment of phagocytic cells (Ritzel et al., 2015), and thus, these
data are in line with the literature. Previous work has shown that post-
stroke delivery of AAV7-MANF leads to a transient increase of phago-
cytic myeloid cells in the peri-infarct region (Mätlik et al., 2018), and
the neuroprotective effect of MANF has been suggested to be due to
alternative activation of microglia (Neves et al., 2016). It is possible
that S100A8 and S100A9 represent a link in the cascade mediating the
effects of MANF, but this requires further investigation.
5. Conclusions
In conclusion, our results illustrate the molecular fingerprint oc-
curring in the ischemic stroke peri-infarct area, in which the en-
dogenous recovery mechanisms operate, at 4 days post-stroke, the time
point at which these mechanisms are activated. The multiomics ap-
proach utilized in this study yielded complementary data, different
omics levels validating each other and making the picture more com-
prehensive about the biological phenomena discussed in this work. In
addition, we characterized the effects of post-stroke AAV1-MANF ad-
ministration in the peri-infarct region on the transcript, protein, and
metabolite level. While no statistically significant changes between the
animals treated with AAV-MANF and AAV-eGFP were identified in the
metabolomics data, proteomics and transcriptomics data show changes
in genes related to immune response. Whether these changes have
functional consequences in the biological context, needs further in-
vestigation. MANF causes the downregulation of secreted phagocyte
proteins S100A8 and S100A9, pointing towards its possible effect on
the number or activation of phagocytes in the peri-infarct region. The
transcripts related to immune response, especially to the virus, were
upregulated in the MANF group, suggesting that it may affect the im-
mune response to the AAV1 vector. While all of these results require
further validation, they reinforce the previous findings about the im-
munomodulatory effects of MANF.
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